Jan Buter

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

Hisham Mehanna, Max Robinson, A. Hartley et al. · The Lancet · 2018 · 988 citations · Full text

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp et al. · The Lancet Oncology · 2014 · 738 citations

Neuro-oncology, Oncology, Single-agent Bevacizumab +10

A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus

Bernard M. Tijink, Jan Buter, Remco de Bree et al. · Clinical Cancer Research · 2006 · 310 citations · Full text

Oral metastases: report of 24 cases

R.I.F. van der Waal, Jan Buter, I. van der Waal · British Journal of Oral and Maxillofacial Surgery · 2003 · 295 citations · Full text

Surgical Oncology, Oral Metastases, Pathology +6